Piramal Pharma Limited announced its financial results for the year ended March 31, 2026. The company reported standalone revenue of ₹4,782.01 crore and consolidated revenue of ₹8,869.08 crore for FY2026. Alongside its financial disclosures, the company confirmed key leadership re-appointments, including Ms. Nandini Piramal as Chairperson and Executive Director, and announced the appointment of Mr. Maneesh Sharma as the new Company Secretary and Compliance Officer, effective April 29, 2026.
Financial Performance Overview
For the financial year ended March 31, 2026, Piramal Pharma Limited reported a standalone profit after tax of ₹700.01 crore, compared to ₹691.40 crore in the previous year. On a consolidated basis, the company reported a net loss after tax of ₹325.94 crore, reflecting various operational and exceptional items, including a significant ₹175.82 crore impairment charge recognized during the year.
Strategic Leadership Updates
The Board of Directors has approved several key leadership transitions to steer the company’s future growth. Ms. Nandini Piramal has been re-appointed as Whole-Time Director, designated as Executive Director and Chairperson, for a further term of three years starting April 1, 2027. Similarly, Mr. Peter DeYoung has been re-appointed as Whole-Time Director, designated as Executive Director, for a three-year term effective October 6, 2026.
In addition, the Board approved the re-appointment of Independent Directors Mr. Sridhar Gorthi and Mr. Peter Stevenson for a second term of five consecutive years, effective March 30, 2027.
Management and Operational Changes
The company announced a transition in its Key Managerial Personnel. Mr. Maneesh Sharma joins as the Company Secretary and Compliance Officer effective April 29, 2026, taking over from Ms. Pratibha Mishra, who served as the interim lead. Furthermore, the company has updated its registered office address in Mumbai, which will take effect on April 30, 2026, moving to the Ananta Building, Piramal Corporate Park.
Source: BSE
